A b s t r a c t
The introduction of immunophenotyping, cytogenetics, and molecular methods had a major impact on the classification of non-Hodgkin lymphomas. The wide approach of these techniques contributed to the recognition of previously unrecognized phenotypes and the definition of new distinct clinicopathologic entities. Also, there is increasing evidence that a normal counterpart for most neoplastic cells exists. 1 Combining these findings with morphologic features, as well as with clinical findings, reflects a new approach to classifying hematologic disorders. It led to the development of the Revised European-American Lymphoma classification 2 and the proposed World Health Organization international consensus classification. 1 The expression of CD56, a neural cell adhesion molecule, is more common in Asia but now is recognized more frequently in the United States and Europe 3, 4 in malignant lymphomas and leukemias. CD56 is recognized as a marker of natural killer (NK) cells and also is found on a subgroup of T cells, usually CD8+ suppressor cells. [4] [5] [6] It usually is associated with highly aggressive lymphomas. 3, 4, [7] [8] [9] Reports of cases in Asia emphasize an association with the Epstein-Barr virus (EBV). 8, 10 Within CD56+ putative NK-cell lymphomas and NK-T-cell lymphomas, it is rare to find immunophenotypic coexpression with CD4, a marker that usually is expressed in a subset of normal helper T cells. There may be a normal counterpart of CD4+/CD56+ lymphoma cells since these have been reported in patients with chronic hepatitis 11 and kidney allografts. 12 Also, small numbers of CD56+ cytotoxic T cells can be found in the peripheral blood of otherwise healthy persons. 5, 13 We searched our files for cases with this uncommon immunophenotype and found 4 cases with morphologically heterogeneous disease and a clinically variable course. These cases are discussed in this article.
Materials and Methods

Case 1
A 46-year-old African American man with a history of alcoholic liver disease initially was seen in February 1993 with fever, chills, and substantial weight loss during the months before admission. He had splenomegaly but no other abnormalities, such as lymphadenopathy or skin lesions. He was pancytopenic (RBC count, 3.4 × 10 6 /µL [3.4 × 10 12 /L]; hemoglobin, 9.4 g/dL [94 g/L]; WBC count, 1,900/µL [1.9 × 10 9 /L]; and platelet count, 33 × 10 3 /µL [33 × 10 9 /L]). Splenectomy (2,720-g spleen) revealed lymphoma of the large granular lymphocyte type predominantly infiltrating the red pulp with some preservation of the white pulp. Regional lymph nodes, bone marrow, and blood showed no involvement. No chemotherapy was given, and the patient was doing well 4 years after splenectomy. He died in June 1997 of unrelated causes. Sections of spleen, bone marrow, and peripheral blood smears were available for review.
Case 2
A 78-year-old white woman was seen in January 1993 with fever and progressive fatigue. Four months before admission a diagnosis of chronic lymphocytic leukemia was made at another institution. She had not received treatment. Physical examination revealed splenomegaly but no palpable lymphadenopathy or skin lesions. She had large granular lymphocytosis (287,000/µL [287.0 × 10 9 /L]) and thrombocytosis (1,341 × 10 3 /µL [1,341 × 10 9 /L]). A bone marrow biopsy was performed that showed large granular lymphocytosis. The patient died a few days after the diagnosis was made. A peripheral blood smear and a bone marrow biopsy specimen were available for review.
Case 3
A 47-year-old previously healthy white man sought care at another institution in June 1995 because of cutaneous masses on his back. Laboratory data were not available. Skin biopsies revealed a predominantly subcutaneous malignant lymphoma, large cell type, with a perivascular and periadnexal distribution. Tumor cells were not seen within the epidermis. Four months after the initial diagnosis, an acute leukemic phase developed (WBC count, 140,000/µL [140 × 10 9 /L]; blasts, 92%), and the patient died in November 1995. Skin biopsy specimens and peripheral blood samples from the leukemic phase were available for review.
Case 4
A 35-year-old Arab-American man sought care in September 1997 because of a 1-year history of cutaneous lesions on his lower extremities. Physical examination did not reveal additional organ involvement, specifically no lymphadenopathy or tonsillar enlargement. The diagnosis of a cutaneous T-cell lymphoma was made on a skin biopsy, and the patient underwent 6 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) with complete response in January 1998. In May 1998, he returned with painful skin lesions on his neck and upper and lower extremities. A bone marrow biopsy was performed that showed no evidence of involvement. In January 1999, he had tonsillar enlargement and diffuse cervical and axillary lymphadenopathy. A tonsillectomy and lymph node biopsy revealed involvement by lymphoma. A second course of chemotherapy was started for progression of the lymphoma, and the patient underwent bone marrow transplantation in the fall of 1999. He experienced another relapse after 6 months and had multiple skin lesions. Lymph node, tonsil, and bone marrow biopsy specimens were available for review.
Morphologic Examination
Tissue specimens from spleen (case 1), bone marrow (case 2), skin (case 3), and tonsil and lymph node (case 4) were fixed in 10% nonbuffered formalin. Formalin-fixed, paraffin-embedded specimens were cut in 4-µm sections and stained with routine H&E for histologic evaluation. Smeared bone marrow cells and peripheral blood cells were stained with Leishman stain. Cytochemical stains including myeloperoxidase, Sudan black, nonspecific esterase, and alpha-naphthyl AS-D chloroacetate esterase were performed.
Immunophenotyping
Immunophenotyping was performed on formalin-fixed, paraffin-embedded tissue and on cryostat sections using the avidin-biotin-peroxidase method (case 1 entirely and cases 2-4 in part). Monoclonal mouse antibodies to CD2, CD3, CD4, CD8, CD16, CD19, CD20, CD30, CD56, CD57, and HLA-DR (Becton Dickinson, San Jose, CA); LMP-1 (DAKO, Carpinteria, CA); terminal deoxynucleotidyl transferase (TdT; Supertechs, Bethesda, MD); TIA-1 (Coulter, Miami, FL); and Mib-1 (Novacastra/Vector Laboratories, Burlingame, CA) were used. For case 3, anaplastic lymphoma kinase (ALK) (DAKO) also was used.
Immunophenotyping of cases 2, 3, and 4 also was performed by 3-color flow cytometry (FACScan, Becton Dickinson, Mountain View, CA). Bone marrow (case 2), peripheral blood (case 3), and tonsillar tissue (case 4) were evaluated using monoclonal mouse antibodies to HLA-DR, CD2, CD3, CD4, CD5, CD8, CD16, CD19, CD20, CD33, CD56, and CD57 (Becton Dickinson).
Gene Rearrangements
High-molecular-weight DNA was extracted and purified from frozen tissue specimens using the Puregene DNA © American Society of Clinical Pathologists extraction kit (Gentra Systems, Minneapolis, MN). T-cell gene rearrangements were analyzed by Southern blot and Tgamma polymerase chain reaction (PCR). For the T-cell receptor (TCR) beta chain Southern blot assay, 5 µg each of the sample DNA, negative control placenta DNA, and positive control TCR beta rearranged DNA was digested overnight using the restriction endonucleases EcoRI, BamHI, and HindIII (New England Biolabs, Beverly, MA). The resulting fragments were size separated by gel electrophoresis on an 0.8% agarose gel and transferred onto a Hybond N+ nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ). The membrane was then hybridized with a TCR beta probe that had been radiolabeled with phosphorus 32 by the random oligonucleotide priming technique. The TCR beta probe contains fragments of the constant region of the human TCR beta chain. Hybridizations and washings were performed under stringent conditions, and autoradiographic exposures on Kodak X-AR x-ray film (Sigma-Aldrich, St Louis, MO) were carried out at -70°C for 3 days.
For the T-gamma PCR, amplification was performed using a consensus primer set on the variable (V) region (AGGGTTGTGTTGGAATCAGG) and the other to the joining (J) region (CGTCGACAACAAGTGTTGTTCCAC). The normal polyclonal smear was in the range of 160 to 190 base pairs. Monoclonal bands were indicated by the presence of discrete bands within this smear. Two subsequent PCR reactions were performed. The first reaction was a linear amplification, using only the J primer, and the second was an exponential amplification using both the J and V primers. The reaction mixture consisted of 1× Perkin-Elmer PCR Buffer II (Applied Biosystems, Foster City, CA), a 2-mmol/L concentration of magnesium chloride, 125 µmol of each deoxynucleotide, 0.15 µmol of primer J, 1 to 2 µg of DNA, and 0.5 U of Taq I DNA polymerase in a total volume of 20 µL. The entire linear amplified PCR product then was used as a DNA template for the next PCR reaction, which contained the same concentration of each reagent with the exception of a 1-µmol/L concentration of each primer. The total volume was 40 µL. Both PCR cyclings were performed with 35 cycles at 94°C for 30 seconds, 55°C for 45 seconds, and 72°C for 45 seconds. Ten microliters of the amplified PCR product were analyzed on a 4.0% Maetaphor agarose gel (BioWhittaker, Rockland, ME) for 16 hours at 80 V and visualized with ethidium bromide staining. For case 1, gene rearrangement studies for TCR gamma were performed by PCR on formalin-fixed tissue at a reference laboratory.
Cytogenetic Studies
Cytogenetic studies were performed according to standard protocols. Briefly, 3 cultures were set up in 10 mL of RPMI medium supplemented with 20% fetal calf serum and antibiotic. One culture was grown without stimulation. The other 2 cultures were stimulated for 4 to 5 days with pokeweed mitogen 1:100 (Gibco BRL, Grand Island, NY) or lipopolysaccharide 100 µg/mL (Sigma-Aldrich). All cultures were incubated at 37°C with 5% carbon dioxide. At the end of incubation, colcemid was added to the cultures for 45 minutes, and harvesting was done according to standard procedure. Q banding was used for chromosome identification. Karyotypes were defined according to the International System for Human Cytogenetic Nomenclature. The rearrangements were regarded as clonal if at least 2 cells carried the same abnormality.
In Vitro Test for NK Cell Activity
NK cell activity was measured in a standard 4-hour chromium 51 ( 51 Cr) release assay. Briefly, 1 × 10 6 K562 target cells were labeled with 100 µCi of 51 Cr for 1 hour. Effector cells were isolated from peripheral blood using a standard density gradient separation technique. In roundbottom microtiter plates, 5,000 labeled target cells (0.1 mL) were mixed with various numbers of effector cells (0.1 mL) in doubling dilutions 2.5:1 to 40:1. Triplicate samples were used. Cells were centrifuged gently and incubated at 37°C. After 4 hours, 0.05 mL of medium was added to each well, and the plate was centrifuged. Then, 0.1 mL of the supernatant was removed from each well and assayed for 51 Cr release in an automated gamma counter.
EBV Studies
Two methods, immunohistochemical staining and an in situ method (Ventana, Tucson, AZ), were used to determine EBV status on paraffin-embedded tissue by using a monoclonal mouse anti-EBV LMP-1 antibody (DAKO).
Results
Histories and physical findings are summarized in ❚Table 1❚. The results of immunophenotyping and gene rearrangement studies are summarized in ❚Table 2❚ and cytogenetics studies in ❚Table 3❚.
Case 1
The 2,720-g spleen showed diffuse infiltration of the red pulp by medium-sized, mature-appearing lymphocytes. These cells had vesicular nuclei without prominent nucleoli and moderate amounts of cytoplasm with variably sized granules ❚Image 1❚. Rare mitotic activity was noted. There was focal preservation of the white pulp, and the remaining spleen showed multiple small infarcts. Review of peripheral blood and bone marrow samples showed no involvement by malignant cells. Immunohistochemical studies revealed a CD2+/CD3+/CD4+/CD8-/CD56+/CD57-phenotype. B-cell markers (CD19 and CD20) and the activation markers HLA-DR and TdT were negative. Scattered CD16 positivity was noted. Proliferative activity within malignant cells, as determined by Mib-1, was less than 10%. Stains for EBV were negative. Strong positive TIA-1 staining was noted within malignant cells in a dot-like pattern (Image 1, insert). TCR gene rearrangement studies showed germline configuration for JH (immunoglobulin heavy chain) and TCR beta and a gene rearrangement of the TCR gamma. Cytogenetics showed numerous nonclonal abnormalities. 
Case 2
The peripheral smear demonstrated numerous large lymphoid cells that appeared hypogranular and contained poorly visible cytoplasmic granules ❚Image 2❚. Morphologic review of the bone marrow showed a diffuse interstitial increase of lymphoid cells. Flow cytometry was performed on these lymphocytes and revealed a CD2+/CD3+/CD4+/ CD5+/CD8-/CD56+/CD57-phenotype. B-cell markers were negative, as were the activation markers TdT and HLA-DR. Stains for EBV had to be performed on bone marrow sections. No cytoplasmic staining was identified. TCR beta and JH gene rearrangement studies on peripheral blood showed germline configuration. TCR gamma rearrangement studies were not available for this case. Cytogenetic studies showed few hypodiploid cells with multiple complex abnormalities (Table 3) . TIA-1 stains could not be performed. In this case, an in vitro test for NK activity was performed and showed absence of NK activity.
Case 3
Skin biopsies revealed a dermal patchy infiltrate of large lymphoid cells in a predominantly perivascular and periadnexal distribution. Cytologically, these cells had pale cytoplasm and large, irregularly shaped vesicular nuclei with centrally located prominent nucleoli ❚Image 3❚. There were numerous mitoses and a high proliferative rate (50% positivity with Mib-1). Four months later, the peripheral blood showed a WBC count of 140,000/µL (140.0 × 10 9 /L), 92% of which were large blasts (Image 3, inset). All cytochemical stains were negative. The leukemic cells showed a CD2+/CD3-/CD4+/CD7+/CD8-/CD56+/CD57-phenotype. HLA-DR was positive. Pan B-cell markers, CD10 (common acute lymphoblastic leukemia antigen [CALLA]), and TdT were negative. CD30 (Ki-1) and ALK also were negative. A weak coexpression of CD33, a myeloid marker, was noted in 77% of cells. Stains for EBV were negative. Scattered positivity for TIA-1 was noted within ❚Image 1❚ (Case 1) Spleen (H&E, ×200; inset, immunohistochemical stain for TIA-1, ×200).
❚Image 2❚ (Case 2) Peripheral blood, mature large granular lymphocytes with poorly visible cytoplasmic granules (Leishman, ×1,000). Inset, note small faint granules (Leishman, ×4,000).
blasts in small clusters. Gene rearrangement studies for TCR beta and TCR gamma showed germline configuration. Cytogenetic studies revealed a t(2;5)(p23,q35) translocation.
Case 4
Bone marrow biopsy, skin, tonsillar, and lymphoid tissue samples were reviewed. The tonsil and lymph node samples showed a predominantly interfollicular expansion by sheets of monomorphic intermediate-sized cells with moderate amounts of cytoplasm, nuclei with open chromatin, and small nucleoli ❚Image 4❚. Mitoses were frequent. The skin showed a dense dermal superficial infiltrate by abnormal lymphocytes with an irregular outline and small amounts of cytoplasm. Flow cytometric and immunohistochemical phenotyping of tonsillar tissue revealed a CD2-/ CD3-/CD4+/CD8-/CD56+/CD57-phenotype. B-cell markers and CD10 (CALLA) were negative, the activation marker HLA-DR was positive in 84% of cells, and TdT was weakly positive. No CD33 positivity was noted. Immunohistochemical stains for CD16 and CD30 (Ki-1) were negative. Proliferative activity within malignant cells, as determined by Mib-1, was 50%. Stains for EBV were negative. TIA-1 staining was negative within tumor cells and limited to infiltrating nonneoplastic lymphoid cells. TCR gene rearrangement studies showed germline configuration of JH, TCR beta, and TCR gamma. Cytogenetics were performed on tonsillar tissue and showed an abnormal karyotype that included partial deletions of the long arm of chromosome 6, which are frequent in lymphoid malignant neoplasms.
Discussion
The expression of CD56, a neural cell adhesion molecule, is uncommon in malignant lymphomas, and within CD56+ hematopoietic malignant neoplasms, coexpression of CD4 is an infrequent finding. We report 4 cases of lymphomas/leukemias with a CD56+/CD4+ phenotype that are morphologically, immunophenotypically, cytogenetically, and clinically diverse.
Based on morphologic features, 2 cases (1 and 2) had lymphomas/leukemias of mature large granular lymphocytes (LGLs). One of the patients had pancytopenia and splenomegaly but no clinical evidence of leukemia, lymphadenopathy, or cutaneous disease. He was treated with splenectomy and without adjuvant chemotherapy. Based on immunophenotyping and the presence of a TCR gamma rearrangement, this lymphoma was classified as a T cell-derived neoplasm (CD2+/CD3+/CD4+/CD56+). There was strong staining of cytotoxic granules with TIA-1. The other patient with mature LGL morphologic features and splenomegaly had a clinically acute, rapidly fatal leukemia. There was bone marrow involvement but no lymphadenopathy. The immunophenotypic profile was similar to the previous case. This neoplasm was classified as a T-cell large granular lymphocytic leukemia based on surface CD3 positivity on flow cytometry. In this case, an in vitro test for NK activity was performed, and results were negative. Leukemias of large granular lymphocytes can have variable clinical manifestations, and most CD3+ disorders are reported to follow a chronic course. 14 To our knowledge, there has been only 1 previous report of a CD3+ LGL ❚Image 3❚ (Case 3) Skin biopsy (H&E, ×100). Inset, peripheral blood smear, leukemic phase (Leishman, ×4,000).
❚Image 4❚ (Case 4) Tonsil (H&E, ×100). Inset, morphologic features (H&E, ×400). © American Society of Clinical Pathologists leukemia with a CD56+/CD4+ phenotype, which was a study on nine Chinese patients. 15 This case also followed an aggressive clinical course, and the patient died within 1 month of initial examination.
The 2 remaining patients had a dermal infiltrate of medium-sized cells with blastic morphologic features and prominent nucleoli. Case 3 had a CD2+/CD3-/CD4+/ CD8-/CD56+ phenotype, while case 4 was negative for CD2. In both cases, there was strong positivity for HLA-DR. Also, both cases had high proliferative activity. Case 3 was negative for TdT and showed only a few clusters of blasts with cytotoxic granules (TIA-1), while case 4 was weakly positive for TdT and negative for TIA-1. Both cases were classified as NK malignant neoplasms (IgH, TCR beta, and TCR gamma in germline configuration; CD3-). EBV studies were negative. There are several reported cases with similar clinical and phenotypic findings in the more recent literature. [16] [17] [18] [19] It has been suggested that some of these CD56+/CD4+ cases may constitute a new hematologic entity. 19 This entity would, however, be closely related to the recently described blastoid NK-cell lymphoma. [18] [19] [20] Within this entity, at least some cases are reported to be CD4+/CD56+ and negative for TdT and EBV. 18 CD2 in reported cases showed variable expression. [18] [19] [20] Interestingly, case 3 revealed a t(2;5)(p23;q35) translocation. This cytogenetic abnormality has been associated with anaplastic large cell lymphoma of the NK phenotype and results in dysregulation of the ALK gene on chromosome 2p23. 21 Some authors believe that in anaplastic large cell lymphomas, this finding is associated with a favorable prognosis. 22 We did not observe this in our case. Our case was CD30-and showed aggressive leukemic disease progression; the patient died within a few months. In the fourth patient (case 4), tonsillar and lymph node involvement evolved, and the patient underwent bone marrow transplantation 2 years after initial diagnosis. He experienced relapse several months later with extensive skin involvement.
Reports of lymphomas/leukemias with a CD56+/CD4+ phenotype confirm that most patients have predominantly extranodal disease and that this frequently is associated with initial skin involvement or development of cutaneous disease at a later stage. 3, [16] [17] [18] [19] [23] [24] [25] [26] [27] Most CD56+ hematologic neoplasms are associated with an aggressive clinical course. [7] [8] [9] 28 Although this is true in many CD56+/CD4+ neoplasms, some patients experienced prolonged survival. 17, 29 We noted this in 1 of 4 patients (case 1). While CD56+ nasal T-NK neoplasms, especially in patients of Asian origin, show a very high association with latent EBV infection, 8 it seems more variable within other CD56+ extranodal neoplasms. Some reports emphasize an absence of EBV in subgroups of extranodal lymphomas, such as the blastoid variant of NK lymphoma or neoplasms of proven T-cell lineage. 9, 18, 20 It has been suggested that EBV positivity is generally lower among white patients. 18, 20 In the blastoid NK lymphoma, it remains to be determined whether absence of EBV is related to ethnicity or disease entity. 18 None of the cases we report had evidence of latent EBV infection.
Within CD56+ lymphomas, the issue of lineage assignment has not been settled entirely. 8, 10 Hematopoietic development is thought to originate from a pluripotent stem cell with gradual restriction of lineage potential. There is evidence to suggest that T cells and NK cells are more closely related to each other than to B cells. 6 CD56, an antibody to the neuronal adhesion molecule N-CAM, is considered to be a useful marker for NK cells. 7, 30, 31 However, this marker also is seen on a small percentage of T cells carrying CD3, CD4, or CD8. 5, 13, 32 Conversely, immunophenotypic markers for T cells such as CD2 and CD7 can be expressed on NK cells. 6, 31, 33, 34 Fetal and activated NK cells express cytoplasmic CD3epsilon protein, which is considered a marker for T cells. 34 Also, NK cells and subgroups of T cells can both express in vitro cytotoxic activity. 6, 32, 33 Therefore, TCR gene rearrangements are considered a requirement to determine a true T-cell phenotype, while NK cells have a germline TCR configuration. 6, 31, 34 The lack of specificity among Tand NK-cell markers is reflected within the Revised European-American Lymphoma classification and the proposed World Health Organization classification for hematopoietic and lymphoid tissues. While it is possible to assign a "physiologic" cell of origin to most B-cell neoplasms, several authors suggest that T-cell/NK-cell malignant neoplasms, based on current knowledge, preferably are categorized by clinical features rather than by cytologic features or phenotype. 9, 20 Nevertheless, most cases currently can be assigned to either T-cell or NK-cell origin based on TCR rearrangement studies and immunophenotyping. 9 Accordingly, 2 of our cases are of T-cell lineage, while the remaining 2 cases are best classified as of NK-cell lineage.
Several authors have proposed that a CD56+/CD4+ phenotype may be present on common precursors to T and NK cells. 6, 16, 19 Based on a case of acute leukemia, Ino et al 35 suggested the presence of a putative precursor cell common to both T and NK lineage in the bone marrow, which lacks TCR gene rearrangements. Petrella et al 19 suggested that these cells represent a certain maturation state, derived from a multipotential stem cell.
Other authors have shown an association between myeloid cells and NK cells. [36] [37] [38] CD33 positivity has been reported in precursor NK-cell leukemia by Scott et al, 37 in association with acute myelogenous leukemia. The authors also suggest that case heterogeneity within CD56+ neoplasms may be attributed to multiple isoforms of this marker due to variable splicing and glycosylation. An association between CD56+ cells and myeloid precursors also has been reported by Suzuki and Nakamura 39 based on their experience with leukemia cases. They differentiate between myeloid/NK precursors (CD34+/CD56+), which are negative for TdT, and blastoid NK precursors (CD4+/CD56+). We noted weak expression of CD33 in 77% of neoplastic cells in 1 case (case 3). Tumor cells in this case were negative for TdT, as mentioned. The presence of a multipotent progenitor is further supported by in vitro studies in which a common progenitor to myeloid, B-lymphoid, and NK cells has been raised within an appropriate microenvironment. 38 However, these findings need further study.
To date, reports on CD56+/CD4+ peripheral blood cells are scarce. The recent literature, however, shows increasing evidence that a normal counterpart to cells with a CD56+/CD4+ phenotype exists. Lanier et al 32 have shown in vitro coexpression of CD56 on cytotoxic and noncytotoxic CD4+ T cells after prolonged exposure to certain stimuli. Vergelli et al 40 reported on CD56+/CD4+ cytotoxic cells in the peripheral blood of patients with multiple sclerosis. They concluded that these cells share functional properties of both T and NK cells, and they proposed a role in organ-specific autoreactivity based on CD56-mediated adhesion. Bachetoni et al 12 reported increased numbers of CD4+/CD56+ lymphocytes within kidney allografts during tubular necrosis and rejection. CD4+/CD56+ cells with cytotoxic activity were furthermore isolated from liver biopsy specimens of patients with hepatitis B virus-associated chronic active hepatitis. 11 In both cases, cytotoxic cells were limited to the affected organs (ie, kidney and liver) and not seen in peripheral blood, excluding the possibility of in vitro artifactual coexpression. In one of these studies, the degree of cytotoxicity correlated with the density of CD56 on cells. 11 Both groups of authors concluded that prolonged antigenic stimulation by mediators of inflammation within a specific microenvironment contributed to the emergence of this unusual phenotype. One additional report describes an increase of CD4+/CD56+ large granular lymphocytes in 2 patients with systemic lupus erythematosus during disease exacerbation. 41 Although CD56 is considered a useful marker for NK cells, it is not lineage specific. In hematologic neoplasms, it also may be responsible for the unusual distribution or biologic behavior of tumors with this phenotype. There are clues to the existence of a physiologic counterpart of CD56+/CD4+ cells that, under nonneoplastic conditions, may represent cells of an activated state or an ill-defined precursor cell. Certain conditions such as chronic stimulation may provide an appropriate microenvironment for expansion of cells with this phenotype. This could potentially lead to an oligoclonal cell proliferation and ultimately to the emergence of monoclonality. Similar mechanisms have been described in the setting of posttransplant proliferative disorders 42 and the development of plasma cell dyscrasias.
Overall, hematologic malignant neoplasms with a CD56+/CD4+ phenotype are rare, but there have been attempts to assign at least some of them to new entities. Meanwhile, further studies are needed to improve our understanding of hematologic neoplasms with this unusual phenotype.
